Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing novel small molecule therapeutics for diseases with unmet medical needs, primarily in the U.S. market. The company relies on strategic alliances, particularly with Japanese pharmaceutical firms, to license product candidates. In December 2009, the company completed the acquisition of Avigen, Inc., integrating Avigen's ibudilast-based program (AV411) with MediciNova's existing program (MN-166).
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(20.4) million | $(21.9) million |
| Operating Expenses | $21.2 million | $22.6 million |
| Research & Development (R&D) | $10.9 million | $13.8 million |
| General & Administrative (G&A) | $10.4 million | $8.8 million |
| Cash & Cash Equivalents | $19.2 million | $19.3 million |
| Total Assets | $94.3 million | $50.2 million |
| Accumulated Deficit | $(247.4) million | $(227.0) million |
| Debt (ARS Loan) | $17.6 million | $0 |
| Debt (Convertible Notes) | $29.3 million | $0 |
Note: The company reported no product revenues. The increase in total assets is primarily due to the acquisition of Avigen and the classification of Auction Rate Securities (ARS) and related assets.
Material Changes vs. Prior Period
- Acquisition of Avigen: In December 2009, MediciNova acquired Avigen, Inc. for a total purchase price of approximately $42.9 million. Consideration included cash, convertible notes, and contingent payment rights. This transaction added $4.8 million in in-process research and development (IPR&D) and $9.1 million in goodwill to the balance sheet.
- Reduction in R&D Expenses: R&D expenses decreased by $2.9 million (21%) compared to 2008. This was driven by the completion of the Phase II clinical trial for MN-166 (Multiple Sclerosis) and the termination of development for several non-prioritized assets (MN-001, MN-029, MN-305). These savings were partially offset by increased spending on the prioritized MN-221 program (Asthma/COPD).
- Investment Portfolio Volatility: The company recorded a net gain of $0.3 million on investment securities and the ARS Put in 2009, compared to a net impairment charge of $1.3 million in 2008. This shift was due to a change in the assumed maturity of Auction Rate Securities (ARS) in the valuation model from seven years to five years.
- Liquidity and Debt: The company secured an $18.1 million loan (ARS Loan) from UBS in early 2009 to fund operations, with a balance of $17.6 million at year-end. Additionally, $29.3 million in convertible notes were issued as part of the Avigen acquisition.
Guidance, Outlook, and Risks
- Strategic Focus: Management intends to focus resources on two prioritized programs: MN-221 (acute exacerbations of asthma and COPD) and the combined MN-166/AV411 program (Multiple Sclerosis and other CNS disorders). Development of other pipeline assets will be limited to activities necessary to maintain license rights or maximize value for potential monetization.
- Outlook: The company expects to continue incurring significant operating losses for the foreseeable future. Management believes existing cash and investment securities are sufficient to fund operations through at least December 31, 2010. Future capital requirements will depend on clinical trial progress and the ability to secure strategic collaborations.
- Key Risks:
- Liquidity: Continued reliance on external financing (equity, debt, or collaborations) to fund operations.
- Investment Portfolio: Significant exposure to illiquid Auction Rate Securities (ARS). While a "Put" option allows sale to UBS at par starting June 2010, the securities are currently valued using discounted cash flow models due to market illiquidity.
- Clinical Development: High risk of failure in clinical trials. Delays in patient enrollment for MN-221 were noted in 2009.
- Intellectual Property: Lack of composition of matter patents for MN-166/AV411 and MN-001, relying instead on method-of-use patents which offer weaker protection.
Investor Verification Checklist
- ARS Liquidity: Verify the status of the UBS "ARS Put" option and the company's ability to liquidate its $26.3 million ARS portfolio at par value starting June 30, 2010.
- Convertible Notes: Review the terms of the $29.3 million convertible notes issued to Avigen shareholders, specifically the conversion price ($6.80/share) and maturity date (June 2011).
- MN-221 Clinical Progress: Monitor enrollment rates and results of the ongoing Phase II trials for MN-221 in acute asthma and COPD exacerbations.
- Strategic Partnerships: Assess progress in securing a strategic collaboration for the MN-166/AV411 program, as the company has paused significant independent development of this asset pending a partner.
- Cash Burn Rate: Confirm that the company's cash runway extends through the end of 2010 as projected, given the ongoing operating losses.